Orphagen Pharmaceuticals, Inc. Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Orphagen Pharmaceuticals, Inc. is a San Diego–based biotechnology research company focused on discovering and developing first-in-class small-molecule therapies that target orphan nuclear receptors. Its work aims to address areas such as immunology, pediatric rare diseases, and cancer by pursuing novel transcription-factor–driven pathways. The firm’s lead oncology program, OR-449, targets the orphan nuclear receptor SF-1 to treat adrenocortical cancer, a rare and aggressive tumor with limited existing options, and may offer a broader precision-therapy approach for SF-1 high head and neck and lung squamous cancers. In addition, Orphagen is developing OR-812 for inflammatory bowel disease, with translational work supported by an NIH SBIR grant. The company operates with a small team and maintains its headquarters on Scranton Road in San Diego, with a recent development highlighting a partnership related to its early programs.